^
    1d
    The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction. (PubMed, Clin Exp Metastasis)
    We analyzed global and Chinese CRLM clinical trials from the Informa database, focusing on fruquintinib, sintilimab, and dual immunotherapy (CTLA-4 + PD-1). Targets analysis shows most have low safety and specificity, but CD34, FLT1, and TP53 exhibit good profiles and potential for CRLM therapy and prognosis. This study, by integrating and analyzing the clinical trial data related to CRLM, aims to conduct an in-depth investigation and evaluate the safety specificity of the treatment targets through reference.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • FLT1 (Fms-related tyrosine kinase 1) • CD34 (CD34 molecule)
    |
    Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    4d
    Systemic Therapy for Advanced Pheochromocytoma and Paraganglioma: Real-World Evidence from a Single Center Cohort. (PubMed, Endocr Relat Cancer)
    In the first-line setting, targeted therapy and SSAs were associated with longer PFS than chemotherapy, with surufatinib and lanreotide showing favorable disease control. SDHx pathogenic variant status did not show a clear association with response to TKIs or temozolomide, underscoring the need for validation in larger cohorts.
    Journal • HEOR • Real-world evidence
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    temozolomide • Sulanda (surufatinib)
    4d
    Integrative Multiscale Analysis Reveals EFNA1-Driven Immune Remodeling Promotes Colorectal Cancer Lymph Node Metastasis. (PubMed, Hum Mutat)
    Our investigation reveals a transcriptionally defined malignant population under IRF9 control that orchestrates immunosuppressive microenvironmental reprogramming via EFNA1-mediated signaling networks. The EFNA1-Linifanib combination may represent a potential therapeutic approach to mitigate anti-angiogenic resistance and restrain metastatic progression in colorectal carcinoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • EFNA1 (Ephrin A1)
    |
    PD-L1 expression
    |
    linifanib (ABT-869)
    5d
    Aberrant VEGFR2 supports tumor growth by extracellular matrix remodeling. (PubMed, Cell Death Dis)
    Pharmacological inhibition of VEGFR2 with tyrosine kinase inhibitors, such as lenvatinib, partially reverted ECM alterations in vitro and in vivo, reducing matrix deposition and modifying its organization. These data identify VEGFR2 as a regulator of tumor ECM dynamics and suggest that its inhibition may restore ECM organization, offering a therapeutic strategy to reprogram the tumor microenvironment and limit cancer progression.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    Lenvima (lenvatinib)
    6d
    TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=364, Not yet recruiting, Tongji Hospital
    New trial
    |
    Lenvima (lenvatinib)
    6d
    PELICAN: A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Imperial College London | Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Oct 2027 | Trial primary completion date: Mar 2028 --> Oct 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV
    6d
    MUC1/CA15-3 identifies a clear cell renal carcinoma characterized by Sunitinib response with a specific metabolic signature. (PubMed, Clin Exp Med)
    MUC1 expressing ccRCC is a high angiogenic tumor that presents characteristics of increased aggressiveness, and a specific metabolic profile. Serum CA15-3 is a marker of poor survival and predicts response of sunitinib in patients with metastatic disease.
    Journal
    |
    MUC1 (Mucin 1)
    |
    sunitinib
    7d
    NRF1 Induces ApoEhigh Cancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma. (PubMed, Cancer Res)
    Furthermore, neutralizing NRG1 enhanced the efficacy of sunitinib in RCC models in vivo. Together, these findings highlight targeting the tumor-promoting functions of ApoEhigh CAFs as a promising approach for treating advanced RCC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NRG1 (Neuregulin 1) • NRF1 (Nuclear Respiratory Factor 1) • APOE (Apolipoprotein E)
    |
    sunitinib
    8d
    Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    axitinib
    8d
    A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    8d
    Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)